{"name":"Amicus Therapeutics","slug":"amicus-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"agalsidase","genericName":"agalsidase","slug":"agalsidase","indication":"Fabry's disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pombiliti","genericName":"CIPAGLUCOSIDASE ALFA","slug":"cipaglucosidase-alfa","indication":"Late-onset Pompe disease","status":"marketed"}]}],"pipeline":[{"name":"agalsidase","genericName":"agalsidase","slug":"agalsidase","phase":"marketed","mechanism":"Biologic","indications":["Fabry's disease"],"catalyst":""},{"name":"Pombiliti","genericName":"CIPAGLUCOSIDASE ALFA","slug":"cipaglucosidase-alfa","phase":"marketed","mechanism":"Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease.","indications":["Late-onset Pompe disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNNDg4bTM2MWZFZ0hkRHZDTlc1ZUl5dWZVY0NFNTlkcU1pRjVWVUFhV2RVQm5yMDJCWVE1YVBBRDV2T2syc3VWZUt2YkMwRUlXTUpCVjVnMGFJbXZaUDJJU3NsXzZ5eEwxVmF6ZkNaQUF1cm5FUkQxLVUwWG8xZzZKUmF0TmtYbFYwUFI3TXR3?oc=5","date":"2026-03-06","type":"pipeline","source":"Yahoo Finance","summary":"How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance","headline":"How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPQzBraWRKbHhKUVFES1FhTm8tYVlsd29WRHNlcEZSZ3VSMVN1WGZYVzhKSjBXMVNEY0hFZWxqRE1RWWduWDZEeU1DeGt1ZTlLRDlUdTFiQm5UZXNSR1FHeURGQ2hGMGVUdlBZQVJ6SThqM1hpZzlGQTROc0pTbkhXb1FCX3ZnTTZzNzItY1l6UmJGMTQ0N2hXN3B3?oc=5","date":"2025-12-29","type":"deal","source":"Contract Pharma","summary":"BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma","headline":"BioMarin to Acquire Amicus Therapeutics for $4.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNS1R6TmEzX3lqTmRaZXczdU1OcEtiTHhnaWZUZG0xaWl1MFJ4QV9GVnVEdkhFUE9YWDRXX0xTQThvYWtGRjFZdlVtRHBtMERWWVJQRmtCNWhZRE55dThQUjd6Znc4STNHMFBJQkFiRmpVZjdZY2p1czd3LUJJMDJMOWtqRjlDald1OWQ2WTlEWmJlODR0ZjI2cjAzNENnWmJoZmhCbU52aw?oc=5","date":"2025-12-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology","headline":"BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBrZVUzYndPRzcyY055TTFtYzdCWHhjNEIwNndRNHBuT180clNuZGYzMVYyeFVZUVlQWEx2ekMwRVZUSDIxRTI2cm1MSTlvLWNrNDJVckhvcnd3VGo3SDkxUkttSndYQlpjUVZYcHBiYW9Hamc?oc=5","date":"2025-12-22","type":"pipeline","source":"pharmaphorum","summary":"BioMarin ends year with $4.8bn play for Amicus - pharmaphorum","headline":"BioMarin ends year with $4.8bn play for Amicus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNN2RGaDl5ekNhbFhvNVRiVTRycU50ckZ3WmgwOUNMMjlWdmREZXVWNzZMVUZjQktqbkxPRWtSNjdEVk9qZzhQSWZ1bFZtYnB6M1U4ZHVPZUpfNE1pLU5SbWdReTBGRTI0cXFUWFpMUUl6YmlYTGxEWDhNczJoN0RIQVF30gGHAUFVX3lxTFBoX1Bxc1dYamNBUk5xUzFNRElKV2VKR29ZMC0tbEIyQlZVd0Q3NUs1UmRvQVlzaENNa0syZHZBalhfdUZpMTlORXdPRnlzVU5SSGFDZWJUT3hlOER1UjBkcE9mdHhURjdJX1BRb0pMRURPem9NZWVCT0FIdlpOdEdHUnJaWU16OA?oc=5","date":"2025-12-19","type":"deal","source":"CNBC","summary":"BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet - CNBC","headline":"BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZTdHcTFtSEU2UmNucFZGdHlTNFN4aWlOeEVMdU9ycmVwR05DV0YtbjBXR0tlSnV6bnhoZ3JLWnlET1JJX25RMTBtejE4UVpZUDRfd2EwNE9UUEZmcy16SFlQSmxNRW9YX2pmLVI5TkRITXZwdWpTZlNMSnY2YXhYcTkzeVIwQ21IN0tkWDU0WmVTbzFyNW9Jd2FNU0NsRXl3VVg3U00zdUNGMWJLM1QxMUIwM3A?oc=5","date":"2025-12-19","type":"pipeline","source":"MedCity News","summary":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News","headline":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPQWVLaS0zZkhicUw1SzhUTTh1ZnNXT2FwU1dnM0duRnF2dTI3SXBvS0FxQXRqNFlyVWwtOEc4anoxVWkxUmRFVE55S2lEZFRaUkdraVBQdkUwX1lzVjJaSnBHVEh0R2VtcFlfMkFlcTZydERpVWtoMUNwZUQwZmZHN1Q3T2pWM2FXWHhLTF9XYVk2UmhRXzE2bm93?oc=5","date":"2025-12-19","type":"deal","source":"BioPharma Dive","summary":"BioMarin to buy rare disease drugmaker Amicus for $4.8B - BioPharma Dive","headline":"BioMarin to buy rare disease drugmaker Amicus for $4.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQeHc5VmZqQ1V5Z0tMZUpzOEFQRUJHTFV3U3VsUWRuaTBKQ0hCa3piMUxNVFZPODJfQ09DbXBUeHl2Wk00aVd2UzVZTzRLVVZqVmZTZ2xuQVVaQlNkMnhSdGlWVWkxQmd4WWJCbGtUWWlVb3FFS3NXclNicDhXQmd6SFVnWTR4N0JsbkZEUFN3dG5qTm03YVZxcWhrNV81QWtTeWtXenB1bFc2NnZX?oc=5","date":"2025-12-19","type":"deal","source":"Pharmaceutical Executive","summary":"BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics - Pharmaceutical Executive","headline":"BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPOGRCZHpZQWt0SjBMWWh1UEpkSk9USWYyY25wLWlib1JpQjBCcEM2U0M1Z2VGY0txWFZ5aEVNYWE4ME43c1ZyRm84UmNfYUhDNU1sR0RFOFE4Wk14ZmlwOElRUzZMT1kxRS1YWkd5UEV4NzI3Vkc1dFNRVDBWbExCZm1WYzFqQkRIaHVOeFhTLUZoVi1BOHNnWHU0ZEVSR3I3X1pCSC1R?oc=5","date":"2025-12-19","type":"deal","source":"reuters.com","summary":"BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet - reuters.com","headline":"BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPN2lraFlNMjl5WlBJUF9uejdwRU00aTBYS3NlUHhYbFVWVjdVRWlxMXVWTmgtZ00zdElyaDdDeFVOd1RjVXdlbC1EazU1Y1dUSUtKYWJUU0ZLMV9LOUlNdnVKcy1sbXlQS2pLeGRZaFZhTFZYV2stTDk5X1Y5RU1LaldPSHE2dzlUaklsTFlpN01lc2l3?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Pharma","summary":"BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus - Fierce Pharma","headline":"BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQdXR4c1p1UllRcXVMLXF6ajBSTmdXbHBwRFRrandjUmNJYkNJQnp4TXRDQ2FNcDdwSVRpNTVfSGIzX1M5WmV0SWF6WXBSYldmdkJYM2JjR3VoVWdPblhQeXRwNC1hLXpEUTJlaWxxb21TVWJvZ0J4Yi1obURtUkdaR29zODdOZ3RIUmF0dk1uOEpnZzdmdW45U3lJYw?oc=5","date":"2025-12-19","type":"deal","source":"WSJ","summary":"BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion - WSJ","headline":"BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNRF9nQU05dGJDVnZXdHU0ZU10SlA2TlZDVlQyZlRqak4zV2NPTjZHZUJlOHhTbXlmbFFjdktrRTJkei1STWgzVTlSbnhXZzhaZ0V1Vm55YUtYNVZ0dWMxU0UwUndSenF0M0hSamYzT0cwUzktOTIxR284MjVhZlM1amFfM1lSNncxWU12Q21NMUc?oc=5","date":"2025-12-19","type":"deal","source":"Barron's","summary":"BioMarin Stock Jumps After Nearly $5 Billion Amicus Therapeutics Deal - Barron's","headline":"BioMarin Stock Jumps After Nearly $5 Billion Amicus Therapeutics Deal - Barron's","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}